The U.S. Food and Drug Administration has approved the use of chewable tablets indicated for the treatment of attention ...

Lisdexamfetamine dimesylate 10mg, 20mg, 30mg, 40mg, 50mg, 60mg; strawberry-flavored. 10 mg – white to off-white round shaped tablet debossed with ‘10’ on one side and ‘S489’ on the other ...

Granules India's subsidiary, Granules Pharmaceuticals Inc, has received approval from the USFDA for its generic version of ...

Granules India gains FDA approval for generic Vyvanse chewable tablets, addressing ADHD and BED drug shortages.

Vyvanse (lisdexamfetamine) is a prescription drug that comes as a capsule and a chewable tablet. It’s usually taken once per day. Vyvanse is used to treat: attention deficit hyperactivity ...

Lisdexamfetamine dimesylate (Vyvanse; New River Pharmaceuticals/Shire), a prodrug of D-amphetamine, was approved by the US FDA in February 2007 for the treatment of ...

The tablets are currently published on the FDA Drug Shortages List, emphasizing their critical role in patient care.

Granules India's subsidiary receives USFDA approval for generic Lisdexamfetamine Dimesylate chewable tablets, a medication ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its ...

Granules India announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug Administration (USFDA) for its ...

The pharmaceutical company, in an exchange filing on Tuesday, said its wholly-owned foreign subsidiary, Granules ...